Stock Price Quote

NATURAL CAPSULES LTD.

NSE : NATCAPSUQBSE : 524654ISIN CODE : INE936B01015Industry : Pharmaceuticals & DrugsHouse : Private
BSE150.55-3.05 (-1.99 %)
PREV CLOSE ( ) 153.60
OPEN PRICE ( ) 154.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 522
TODAY'S LOW / HIGH ( )150.40 156.40
52 WK LOW / HIGH ( )137.5 296.4
NSE151.10-4.68 (-3 %)
PREV CLOSE( ) 155.78
OPEN PRICE ( ) 154.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1861
TODAY'S LOW / HIGH( ) 150.00 155.00
52 WK LOW / HIGH ( )136.36 296
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1993
Management Info
Tekkar Yashwanth Prabhu - Chairman Sunil L Mundra - Managing Director
Registered Office

Address Trident Towers,4th Floor, No. 23, 100 Feet Road,Jaynagar I I Block,
Bengaluru,
Karnataka-560011

Phone 080- 26561562 / 1571 / 1573 / 581

Email info@naturalcapsules.com / company.sec@naturalcapsules.com

Website www.naturalcapsules.com

Registrars Details
Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
Listing : BSE, NSE

NEWS

13Mar Natural Capsules’ arm signs agreements
Natural Capsules’ subsidiary -- Natural Biogenex has executed definitive..
13Mar Natural Capsules jumps as its arm sign
Natural Capsules is currently trading at Rs. 151.00, up by 3.00 points o..
14Nov Natural Capsules informs about investo
Pursuant to Regulation 30 of Securities and Exchange Board of India (Lis..
05Aug Natural Capsules informs about press r
Pursuant to Regulation 30 of Securities and Exchange Board of India (Lis..
05Aug Natural Capsules informs about investo
Pursuant to Regulation 30 of Securities and Exchange Board of India (Lis..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit3.6200000000000167.1199999999999
Gross Profit 4.58000000000001 92.9699999999999
Operating Profit 40.05235.36
Net Sales 341.461679.38

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE)
peergroup  8718.05 (5.14%)
M.Cap ( in Cr)21795.13
Onesource Specialty (BSE)
peergroup  1543.30 (7.37%)
M.Cap ( in Cr)17692.80
Ajanta Pharma (BSE)
peergroup  2895.85 (3.29%)
M.Cap ( in Cr)36179.48
Venus Remedies (BSE)
peergroup  1039.95 (4.61%)
M.Cap ( in Cr)1390.10
Glenmark Pharma (BSE)
peergroup  2194.05 (1.44%)
M.Cap ( in Cr)61916.27

Shareholding Pattern

PROMOTERS 51.26%
NON-INSTITUTION 48.74%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Natural Capsules Ltd.

Natural Capsules Ltd. was incorporated in the year 1993. Its today's share price is 150.55. Its current market capitalisation stands at Rs 156.36 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1679.38 Cr and Total Income of Rs.1723.44 Cr. The company's management includes Pranjal Deshmukh, Jyoti Mundra, Sushil Kumar Mundra, Pramod Kasat, S G Belapure, Sunil L Mundra, Satyanarayan Mundra, Laxminarayan Moondra, Tekkar Yashwanth Prabhu.

It is listed on the BSE with a BSE Code of 524654 , NSE with an NSE Symbol of NATCAPSUQ and ISIN of INE936B01015. It's Registered office is at Trident Towers,4th Floor, No. 23, 100 Feet Road,Jaynagar I I BlockBengaluru-560011, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Gnanoba & Bhat, P Chandrasekar LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.